NCT00051142已完成3 期
A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma or Ocular Hypertension
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 试验地点
- 1
研究概览
简要总结
The purpose of this study is to evaluate the safety and IOP-lowering efficacy of Travoprost (0.004%) compared to Latanoprost (0.005%) in patients with chronic open-angle glaucoma or ocular hypertension.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma or Ocular Hypertensio-H40H40PER-028-02ALCON RESEARCH LTD.,
已完成
2 期
Travoprost New Formulations in Patients With Open-Angle Glaucoma or Ocular HypertensionOpen-angle GlaucomaOcular HypertensionNCT00670033Alcon Research158
已完成
3 期
A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure GlaucomaGlaucoma, Angle-ClosureOcular HypertensionNCT00051181Alcon Research
已完成
4 期
Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular HypertensionGlaucomaNCT00966940Alcon Research51
进行中（未招募）
不适用
The Efficacy and Safety of Travoprost 0.004% versus Tafluprost 0.005% in Primary Open-Angle Glaucoma or Ocular Hypertensive Patients.primary open-angle glaucomaocular hypertensionpigment dispersion glaucomaEUCTR2008-006718-10-DEAlcon Laboratories, Inc.